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Patients with amyotrophic lateral sclerosis (ALS)
may receive the erroneous message, either from
their physicians or through the lay press, that their
disease is untreatable. The error lies in the misin-
terpretation of treatment as cure. There are many
diseases we cannot cure. Treatment in the form of
symptom management has long been a key role of
physicians, nurses, and other health care providers,
as noted by Hippocrates more than 2,000 years
ago: “Cure sometimes, treat often, comfort
always.”1 A cure for ALS remains elusive. Disease
modifying therapies can slow progression or pro-
long survival but cannot improve strength or func-
tion.2,3 Thus, as they have since ALS was initially
described by Charcot in 1869,4 clinicians have
directed their efforts toward optimizing quality of
life (QOL) for persons with ALS and their families
through symptom management.5–7 In doing so, a
multidisciplinary approach to ALS care prolongs
survival and provides improved QOL compared
with conventional care.8,9
The study presented by Nicholson and col-
leagues10 in this issue provides insight into the cur-
rent state of symptom management of a cohort of
ALS patients. Data on the presence and severity of
these symptoms, the degree to which symptoms
were bothersome, and the efficacy of symptom
management were collected. About 31% of those
who were contacted responded. The mean disease
duration was 5 years. In order of decreasing preva-
lence, patients cited fatigue (90%), muscle stiffness
(84%), muscle cramps (74%), shortness of breath
(66%), sleep difficulty (60%), pain (59%), anxiety
(55%), depression (52%), increased saliva (52%),
constipation (51%), pseudobulbar affect (38%),
loss of appetite (37%), and weight loss (29%).
Fatigue was not only the most frequently reported
symptom but also the least frequently treated one.
It is striking that so many other symptoms com-
monly encountered in ALS were found to have low
treatment prevalence: weight loss 22%, pseudobul-
bar affect 29%, sialorrhea 32%, muscle stiffness
39%, pain 44%, and dyspnea 49%. If symptom
management is the best care we have to offer our
patients, then it is concerning that these percen-
tages are so low. Are we missing opportunities to
improve the quality of the lives of our patients
and, if so, why? Mental health care fares no better.
Specifically, this study also calls attention to the
relatively high prevalence of anxiety and depres-
sion, consistent with the overall significant psycho-
logical morbidity noted in patients with ALS.11
Several years ago, a call was issued for further
research into psychological intervention.12 How-
ever, treatment prevalence of anxiety and depres-
sion in this recent large survey was only about
50%, suggesting that the need for effective psycho-
logical intervention remains, to a great degree,
unmet. Why does this continue to be true?
Can some of the blame be attributed to a lack
of awareness of these symptoms on the part of phy-
sicians? This seems unlikely. Attention to the need
for symptomatic treatment of patients with ALS is
not new. The American Academy of Neurology
issued practice parameters in 2009,5,13 identifying
a number of areas in which symptomatic treatment
is important. Many of the symptoms cited at that
time appear prominently in the article by Nichol-
son and colleagues. It is notable that the high
prevalence of fatigue in ALS patients is not a new
finding. It can worsen over the course of the dis-
ease14,15 and has been shown to improve with
modafinil therapy.16
Is the gap in providing adequate symptom man-
agement due to lack of evidence for the efficacy of
such treatments? Most likely, this is at least par-
tially the case. The 2009 American Academy of
Neurology guidelines note varying degrees of evi-
dence for symptomatic treatments. Then and now,
double-blind, placebo-controlled studies were avail-
able for only a few such treatments, such as dextro-
methorphan plus quinidine for pseudobulbar
affect17 and botulinum toxin for sialorrhea.18 The
lack of high-quality clinical trials for the treatment
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of many other symptoms likely leads to the use of
ineffective therapies or to the inconsistent use of
potentially effective ones. Unfortunately, the devel-
opment of more effective symptomatic treatments
will be challenging. Many of the drugs now used to
treat pain, spasticity, and other bothersome symp-
toms of ALS are off-label, and there is little incen-
tive for pharmaceutical companies to sponsor trials
for the treatment of a small population of individ-
uals with a rare disease if these drugs are already
FDA-approved for other more common disorders.
Even if drugs for symptom management are shown
to be effective for those with ALS, payers may
decline to pay for off-label uses.
Could the fault lie with the physician’s training
and self-perception? These may play a role. In the
United States, most physicians who provide ongo-
ing ALS care in large centers are neurologists, few
of whom have received formal training in palliative
care. Effective management of pain or of depres-
sion and anxiety are often learned “on the job.”
Perhaps it is time for us to rethink the training we
provide to those who will be directing such clinics
in the future. It is essential that ALS physicians
avoid misleading generalities or false statements,
such as the lack of treatments for ALS. Evaluating
a long list of possible symptoms that are of poten-
tial concern to the patient at each visit is essential
for good care.
As with all studies, this one has limitations, and
the authors accurately describe some of these. The
study population was limited to those registered
with the Muscular Dystrophy Association, a group
that may not be representative of the ALS popula-
tion as a whole, and about 70% of those to whom
the survey was sent did not return it. Although the
patient population in some ways appears to be rep-
resentative of those with ALS (mean age 60 years,
61% men, 77.8% limb onset), we do not know
whether the 70% of those who chose not to return
their surveys had a different set or frequency of
treated or untreated symptoms. Certainly those
who responded had a longer average duration of
disease than most ALS patients, and the authors
acknowledge this. They may also have differed
from the other 70% or from the ALS population
as a whole with regard to resources such as insur-
ance or access to health care providers and
medications. The authors do not describe how the
survey was developed. Were patients and their care-
givers involved in determining the list of symptoms
about which patients were questioned? Although
respondents could free text responses that were
not on the list of symptoms, they may have been
less likely to do so than to choose from the exist-
ing list, as the authors indicate. This survey could
not address the fact that many symptoms are
moving targets, controlled with therapies one
month but uncontrolled the next or absent
entirely early in the disease and then severe and
bothersome as the disease progresses. Adequate
symptom management requires frequent reassess-
ment of symptom presence and severity. The sur-
vey by Nicholson and colleagues is a snapshot in
time, and longitudinal studies would be useful.
One smaller study looked at evolution of symptoms
and found, not surprisingly, that patients perceived
most symptoms to worsen over time.14 ALS care
providers must be constantly vigilant for new or
worsening symptoms.
The bottom line is that ALS is a terrible disease.
It produces a large number of symptoms that are
bothersome at best and debilitating at worst, each
of which may require active management.6 For
those who are treating patients with ALS, cure is
not yet within reach, but treatment with the goal of
providing comfort should remain a guiding princi-
ple. Nicholson and colleagues remind us that man-
agement of symptoms can be overlooked in ALS
but remains a critical component of treatment and
comfort. Their study provides us with an important
roadmap drawn by our patients, leading to a better
understanding of those symptoms that are most fre-
quent and bothersome to them, providing guid-
ance regarding the extent to which patients are
receiving adequate symptomatic relief. Our job is
to use our patients’ insights and their collective wis-
dom not only to identify the most effective symp-
tom management strategies but also to implement
them aggressively in a process of shared decision
making with our patients. It is essential that ALS
specialist physicians as a group shift our emphasis
from identifying to addressing gaps in treatment and
shortcomings in care. If trained in the modern era,
Hippocrates likely would have understood and
approved of this approach.
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